OBJECTIVES

The objective of this study was to develop and validate an approach to accurately identify incident pediatric neuropsychiatric events (NPEs) requiring hospitalization by using administrative data.

METHODS

We performed a cross-sectional, multicenter study of children 5 to 18 years of age hospitalized at two US children’s hospitals with an NPE. We developed and evaluated 3 NPE identification algorithms: (1) primary or secondary NPE International Classification of Diseases, 10th Revision diagnosis alone, (2) NPE diagnosis, the NPE was present on admission, and the primary diagnosis was not malignancy- or surgery-related, and (3) identical to algorithm 2 but without requiring the NPE be present on admission. The positive predictive value (PPV) of each algorithm was calculated overall and by diagnosis field (primary or secondary), clinical significance, and NPE subtype.

RESULTS

There were 1098 NPE hospitalizations included in the study. A total of 857 confirmed NPEs were identified for algorithm 1, yielding a PPV of 0.78 (95% confidence interval [CI] 0.76–0.80). Algorithm 2 (n = 846) had an overall PPV of 0.89 (95% CI 0.87–0.91). For algorithm 3 (n = 938), the overall PPV was 0.86 (95% CI 0.83–0.88). PPVs varied by diagnosis order, NPE clinical significance, and subtype. The PPV for critical clinical significance was 0.99 (0.97–0.99) for all 3 algorithms.

CONCLUSIONS

We identified a highly accurate method to identify neuropsychiatric adverse events in children and adolescents. The use of these approaches will improve the rigor of future studies of NPE, including the necessary evaluations of medication adverse events, infections, and chronic conditions.

Neuropsychiatric events (NPEs) encompass a range of signs, symptoms, and diagnoses, some of which are life-threatening (eg, psychosis, seizures, and suicidal or homicidal ideation) and lead to emergency health care utilization.1  NPEs can be due to underlying medical conditions, such as depression, epilepsy, or bipolar disorder, infections such as influenza,2  as well as preventable adverse effects of commonly used medications such as stimulants,3  antihistamines,4  antiepileptics,5,6  and antibiotics,79  among others.

Voluntary reports submitted to the FDA Adverse Event Reporting System, as well as published case series and related media reports, have revealed concerns of medication-related NPEs for a number of commonly prescribed pediatric medications, including oseltamivir (Tamiflu), polyethylene glycol (Miralax), and montelukast (Singulair).1013  However, studies rigorously evaluating medication-related NPEs are lacking, in part because licensure clinical trials are usually inadequately powered to identify these uncommon yet potentially serious outcomes. Although some observational studies have used discharge diagnosis codes to identify pediatric NPEs,13,14  the validity of this approach is unknown.

We sought to validate an approach to accurately identify incident pediatric NPEs requiring hospitalization by using administrative data. We aimed to identify one or more algorithms that yielded a positive predictive value (PPV) of ≥ 85% overall and for the critical and important clinical significance cohorts. A PPV of ≥ 85% was chosen to limit misclassification and the impact of residual misclassification on measures of association if the method is used in future studies.

This was a cross-sectional study of children 5 to 18 years of age hospitalized at two US children’s hospitals in the Midwest and South between April 1, 2016 and March 30, 2020 with a discharge International Classification of Diseases, 10th Revision (ICD-10)-coded NPE diagnosis (Supplemental Table 3).1,14,15  The selection of NPE diagnosis codes was informed by previous studies using administrative data to capture NPE1,14  and pediatric mental health disorders15  as well as the review of ICD-10 code books and discussion with content experts (pediatric psychiatrists, pediatricians, hospitalists, pharmacoepidemiologists, and coding experts) to evaluate coding practices (Supplemental Table 3).

TABLE 1

Demographic Characteristics, Overall and by Study Site

CharacteristicOverall, N = 1098Study Site
Midwestern, n = 552South, n = 546
Median age, y, median (IQR) 14.0 (11.0–16.0) 14.3 (11.4–16.2) 13.5 (10.7–15.8) 
 5–11 353 (32) 166 (30) 187 (34) 
 12–18 745 (68) 386 (70) 359 (66) 
Female 571 (52) 294 (53) 277 (51) 
Race or ethnicity    
 Asian 17 (1.5) 9 (1.6) 8 (1.5) 
 Hispanic 144 (13) 119 (22) 25 (4.6) 
 Non-Hispanic Black 107 (9.7) 32 (5.8) 75 (14) 
 Non-Hispanic White 739 (67) 338 (61) 401 (73) 
 Other 91 (8.3) 54 (9.8) 37 (6.8) 
Payer    
 Government 486 (44) 229 (41) 257 (47) 
 Private 559 (51) 316 (57) 243 (45) 
 Other 53 (4.8) 7 (1.3) 46 (8.4) 
 Complex chronic condition 453 (41) 228 (41) 225 (41) 
NPE clinical significance    
 Unclear 87 (7.9) 47 (8.5) 40 (7.3) 
 Important 622 (57) 312 (57) 310 (57) 
 Critical 389 (35) 193 (35) 196 (36) 
CharacteristicOverall, N = 1098Study Site
Midwestern, n = 552South, n = 546
Median age, y, median (IQR) 14.0 (11.0–16.0) 14.3 (11.4–16.2) 13.5 (10.7–15.8) 
 5–11 353 (32) 166 (30) 187 (34) 
 12–18 745 (68) 386 (70) 359 (66) 
Female 571 (52) 294 (53) 277 (51) 
Race or ethnicity    
 Asian 17 (1.5) 9 (1.6) 8 (1.5) 
 Hispanic 144 (13) 119 (22) 25 (4.6) 
 Non-Hispanic Black 107 (9.7) 32 (5.8) 75 (14) 
 Non-Hispanic White 739 (67) 338 (61) 401 (73) 
 Other 91 (8.3) 54 (9.8) 37 (6.8) 
Payer    
 Government 486 (44) 229 (41) 257 (47) 
 Private 559 (51) 316 (57) 243 (45) 
 Other 53 (4.8) 7 (1.3) 46 (8.4) 
 Complex chronic condition 453 (41) 228 (41) 225 (41) 
NPE clinical significance    
 Unclear 87 (7.9) 47 (8.5) 40 (7.3) 
 Important 622 (57) 312 (57) 310 (57) 
 Critical 389 (35) 193 (35) 196 (36) 

Values expressed as n (%) unless otherwise noted. IQR, interquartile range.

Children 5 to 18 years of age admitted to one of two academic children’s hospitals were included in the study. Children < 5 years of age were excluded from the study because neuropsychiatric diagnoses in this age group are not well defined. The study was restricted to hospitalized patients to better identify clinically significant NPEs similar to other Food and Drug Administration studies in children.13  We used a proportional sampling strategy stratified by diagnosis code position (primary or any secondary) to randomly select 1098 encounters with a qualifying NPE diagnosis out of a total of 33 658 hospitalizations with an NPE from the two study sites between April 1, 2016 and March 30, 2020. Electronic medical records were manually reviewed for each encounter and data extracted for analysis included demographic data, race, and ethnicity designation (as reported in the electronic health record) and concurrent diagnoses. Demographic data were included for descriptive purposes only. Complex chronic conditions were classified by using the pediatric complex chronic conditions classification system, version 2.16 

NPE codes were categorized by clinical significance (eg, critical, important, or unclear) and subtype (eg, neurologic or psychiatric) on the basis of expert opinion (Supplemental Table 3). The critical category includes homicidal, suicidal, or self-harm ideation or attempts; the important category includes mood disorders (including anxiety and stress), psychosis, hallucination, altered mental status, ataxia or movement disorders, encephalitis or encephalopathy, and seizures; and the unclear significance category consisted of dizziness, headache, sleeping disorders, and vision changes.

The primary outcome was a physician-confirmed NPE that was present on admission and directly related to hospitalization. This gold standard outcome definition of a confirmed case was used to evaluate each qualifying NPE encounter. To be considered a confirmed case, the description of the event (as listed in history of present illness, physical examination, or assessment and plan), was required to match the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition definition for psychiatric events or be consistent with a description of a prespecified neurologic event. To determine if the NPE was related to the hospitalization, a pediatrician reviewed each case and determined whether the NPE was not related to hospitalization, an active hospital problem present on admission and related to hospitalization, not present on admission but active hospital problem, or a problem present on admission but not related to hospitalization. Reviewers were blinded to the NPE diagnosis and algorithm information. A true positive was defined as an active hospital problem present on admission and related to hospitalization. Independent reviews of a random sample of 50 records by two pediatricians at each site demonstrated excellent interrate reliability with 92% concordance in NPE determinations (κ = 0.80).

We evaluated 3 NPE algorithms using an iterative approach (Supplemental Table 4): (1) NPE diagnosis in either primary or any secondary diagnosis fields, (2) identical to algorithm 1 but with the requirement that the NPE was present on admission and the primary diagnosis was not malignancy- or surgery-related, and (3) identical to algorithm 2 but without requiring the NPE be present on admission. For the algorithms, presence on admission was determined by the presence of a “present on admission” flag assigned to the diagnosis. The present on admission flag is assigned for hospitalized patients and is a data element available in administrative databases.

NPE diagnoses were categorized on the basis of clinical significance on the basis of expert opinion (Supplemental Table 3). We determined the PPV of the proposed identification algorithms, overall and stratified by diagnosis order (primary or any secondary), clinical significance (critical, important, unclear, critical, or important), and NPE subtype (neurologic or psychiatric). Details of the primary and secondary algorithms identified can be found in Supplemental Table 4. The institutional review board at our institution determined that this study of deidentified data did not constitute human subjects research (IRB 201677).

There were 1098 NPE hospitalizations included in the study (Table 1). A total of 857 confirmed NPEs were identified by algorithm 1, yielding a PPV of 0.78 (95% confidence interval [CI] 0.76–0.80). Algorithm 2 examined 846 confirmed NPE hospitalizations and had an overall PPV of 0.89 (95% CI 0.87–0.91). For algorithm 3 (938 confirmed NPE hospitalization), the overall PPV was 0.86 (95% CI 0.83–0.88). PPVs varied by diagnosis order, NPE clinical significance, and subtype. The PPV for critical clinical significance was 0.99 (0.97–0.99) for all 3 algorithms (Table 2).

TABLE 2

Positive Predictive Values of Neuropsychiatric Events

Algorithm 1Algorithm 2aAlgorithm 3b
NPPV (95% CI)NPPV (95% CI)NPPV (95% CI)
Any NPE (n = 1098) 857 0.78 (0.76–0.80) 846 0.89 (0.87–0.91) 938 0.86 (0.83–0.88) 
Diagnosis order       
 Primary ± secondary 653 0.98 (0.96–0.99) 653 0.98 (0.96–0.99) 653 0.98 (0.96–0.99) 
 Secondary only 445 0.49 (0.44–0.54) 193 0.61 (0.54–0.67) 285 0.57 (0.51–0.63) 
Clinical significancec       
 Critical 389 0.99 (0.97–0.99) 384 0.99 (0.98–0.99) 387 0.99 (0.97–0.99) 
 Important 622 0.68 (0.64–0.72) 430 0.82 (0.78–0.85) 493 0.78 (0.73–0.81) 
 Unclear significance 87 0.56 (0.46–0.66) 32 0.72 (0.55–0.84) 58 0.67 (0.54–0.78) 
 Critical or important 1011 0.80 (0.77–0.82) 814 0.90 (0.88–0.92) 880 0.87 (0.84–0.89) 
NPE subtyped       
 Neurologic 438 0.69 (0.65–0.74) 285 0.85 (0.80–0.88) 343 0.78 (0.74–0.83) 
 Psychiatric 660 0.84 (0.81–0.86) 561 0.92 (0.89–0.94) 595 0.90 (0.87–0.92) 
Algorithm 1Algorithm 2aAlgorithm 3b
NPPV (95% CI)NPPV (95% CI)NPPV (95% CI)
Any NPE (n = 1098) 857 0.78 (0.76–0.80) 846 0.89 (0.87–0.91) 938 0.86 (0.83–0.88) 
Diagnosis order       
 Primary ± secondary 653 0.98 (0.96–0.99) 653 0.98 (0.96–0.99) 653 0.98 (0.96–0.99) 
 Secondary only 445 0.49 (0.44–0.54) 193 0.61 (0.54–0.67) 285 0.57 (0.51–0.63) 
Clinical significancec       
 Critical 389 0.99 (0.97–0.99) 384 0.99 (0.98–0.99) 387 0.99 (0.97–0.99) 
 Important 622 0.68 (0.64–0.72) 430 0.82 (0.78–0.85) 493 0.78 (0.73–0.81) 
 Unclear significance 87 0.56 (0.46–0.66) 32 0.72 (0.55–0.84) 58 0.67 (0.54–0.78) 
 Critical or important 1011 0.80 (0.77–0.82) 814 0.90 (0.88–0.92) 880 0.87 (0.84–0.89) 
NPE subtyped       
 Neurologic 438 0.69 (0.65–0.74) 285 0.85 (0.80–0.88) 343 0.78 (0.74–0.83) 
 Psychiatric 660 0.84 (0.81–0.86) 561 0.92 (0.89–0.94) 595 0.90 (0.87–0.92) 
a

Retention of true positive cases (88.2%).

b

Retention of true positive cases (93.6%).

c

Critical: homicidal, suicidal or self-harm ideation or attempt. Important: mood disorders, psychosis, hallucinations, altered mental status, ataxia, movement disorders, encephalitis, seizures. Unclear significance: dizziness, headache, sleeping disorders, vision changes.

d

Neurologic: altered mental status, ataxia, movement disorder, encephalitis, seizures, dizziness, headache, sleeping disorders, and vision changes. Psychiatric: homicidal, suicidal or self-harm ideation or attempt, mood disorders, psychosis, hallucination.

We report 3 algorithms for the identification of incident pediatric NPE with PPVs between 0.78 and 0.89. Algorithm 2, which required both NPE present on admission status and the exclusion of surgical and malignancy primary diagnoses, had the highest PPV while retaining more than 88% of true positive cases. Cases of critical or important clinical significance comprised the most cases and were most accurately identified with algorithm 2. This algorithm specifically identifies acute NPEs related to hospitalization rather than NPEs that occurred during hospitalization but unrelated to admission (eg, ICU delirium) and those present on admission but unrelated to hospitalization (eg, chronic conditions).

Although algorithm 1 has been used for the identification of NPEs in previous studies,1,14,17  we found that this approach introduces misclassification of NPEs. The enhanced algorithms presented in this study more accurately identify NPEs and may reduce outcome misclassification on relative measures of association.

Pediatric NPEs are commonly reported as a result of underlying chronic conditions, infections, medications, and other exposures.2,11,18,19  Evaluating new onset NPEs in observational data is challenging because of the low overall frequency of the events. Studies that examine the association between medications and NPEs are usually focused on identifying new or incident NPEs. To enable proper assessments of medication effects, accurate identification of NPEs is necessary. In addition, it is important to identify the timing of the NPEs relative to the study medication use (eg, whether NPEs were already present), as well as other potential explanations that may introduce misclassification of outcomes (eg, NPEs that started during the immediate postoperative period or chemotherapy) and distort study findings. Acknowledging that there are multiple ways to identify NPEs, our study evaluated the performance of different approaches to accurately identify incident NPEs to inform the selection of outcome measurements for future studies.

This study used data from twochildren’s hospitals. We did not assess NPEs in the ambulatory setting or NPEs that did not result in health care encounters, limiting applicability to milder NPEs and other settings. We did not identify true or false negative cases of NPE and, therefore, could not determine the sensitivity, specificity, or negative predictive value of the algorithms. However, we consider that our determination of PPVs is the most informative element for studies that plan to evaluate the association between medication use and NPEs.20 

The enhanced algorithms presented in this study accurately identify NPEs resulting in pediatric hospitalizations. The use of these approaches can reduce the misclassification of study outcomes and improve the rigor of future studies of NPE. In particular, these approaches may aid in the timely evaluation of NPEs related to new exposures, such as SARS-CoV-2 infections,19,21  and investigating NPE signals in adverse events reporting databases.9,11,22,23  These approaches may also be used to evaluate the effectiveness and safety of treatments for chronic diseases such as depression, bipolar disorder, or epilepsy.

FUNDING: Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under award numbers K12 HL137943 (Dr Antoon), The Vanderbilt University Medical Center Turner Hazinski Award (Dr Antoon), the National Institute for Allergy and Infectious Diseases K24 AI148459 (Dr Grijalva) and R01 AI125642 (Dr Williams), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development K23 HD091295 (Dr Feinstein). The funder/sponsor did not participate in the work. Funded by the National Institutes of Health (NIH).

CONFLICT OF INTEREST DISCLOSURES: The authors have no conflicts of interest relevant to this article to disclose.

Dr Antoon led the overall conceptualization and design of the study, analyzed and interpreted the data, drafted the initial manuscript, and reviewed and revised the manuscript; Drs Gay and Zhu and Mr Sekmen led the acquisition and analysis of the data and contributed to the conceptualization and design of the study and drafting and critical review of the manuscript; Drs Tanguturi and Feinstein contributed to the overall conceptualization and design of the study, provider chart review, interpretation of data, and critical review of the manuscript; Mr Johnson, Ms Dickinson, and Ms Stassun contributed to the acquisition and interpretation of data, and critical review of the manuscript; Drs Williams and Grijalva contributed to the overall conceptualization and design of the study, analysis and interpretation of data, and critical review of the manuscript; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

1.
Huh
K
,
Kang
M
,
Shin
DH
,
Hong
J
,
Jung
J
.
Oseltamivir and the risk of neuropsychiatric events: a national, population-based study
.
Clin Infect Dis
.
2020
;
71
(
9
):
e409
e414
2.
Antoon
JW
,
Hall
M
,
Herndon
A
, et al
.
Prevalence, risk factors, and outcomes of influenza-associated neurologic complications in children
.
J Pediatr
.
2021
;
239
:
32
38.e5
3.
Moran
LV
,
Ongur
D
,
Hsu
J
,
Castro
VM
,
Perlis
RH
,
Schneeweiss
S
.
Psychosis with methylphenidate or amphetamine in patients with ADHD
.
N Engl J Med
.
2019
;
380
(
12
):
1128
1138
4.
Gupta
A
,
Chadda
R
.
Adverse psychiatric effects of non-psychotropic medications
.
BJPsych Adv
.
2016
;
22
(
5
):
325
334
5.
Perucca
P
,
Gilliam
FG
.
Adverse effects of antiepileptic drugs
.
Lancet Neurol
.
2012
;
11
(
9
):
792
802
6.
White
JR
,
Walczak
TS
,
Leppik
IE
, et al
.
Discontinuation of levetiracetam because of behavioral side effects: a case-control study
.
Neurology
.
2003
;
61
(
9
):
1218
1221
7.
Quickfall
D
,
Daneman
N
,
Dmytriw
AA
,
Juurlink
DN
.
Metronidazole-induced neurotoxicity
.
CMAJ
.
2021
;
193
(
42
):
E1630
8.
Pachi
A
,
Bratis
D
,
Moussas
G
,
Tselebis
A
.
Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients
.
Tuberc Res Treat
.
2013
;
2013
:
489865
9.
Bennett
AC
,
Bennett
CL
,
Witherspoon
BJ
,
Knopf
KB
.
An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency
.
Expert Opin Drug Saf
.
2019
;
18
(
11
):
1055
1063
10.
Hussain
SZ
,
Belkind-Gerson
J
,
Chogle
A
, et al
.
Probable neuropsychiatric toxicity of polyethylene glycol: roles of media, internet and the caregivers
.
GastroHep
.
2019
;
1
(
3
):
118
123
11.
Hoffman
KB
,
Demakas
A
,
Erdman
CB
,
Dimbil
M
,
Doraiswamy
PM
.
Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012
.
BMJ
.
2013
;
347
:
f4656
12.
Schumock
GT
,
Lee
TA
,
Joo
MJ
,
Valuck
RJ
,
Stayner
LT
,
Gibbons
RD
.
Association between leukotriene-modifying agents and suicide: what is the evidence?
Drug Saf
.
2011
;
34
(
7
):
533
544
13.
Sansing-Foster
V
,
Haug
N
,
Mosholder
A
, et al
.
Risk of psychiatric adverse events among Montelukast users
.
J Allergy Clin Immunol Pract
.
2021
;
9
(
1
):
385
393.e12
14.
Harrington
R
,
Adimadhyam
S
,
Lee
TA
,
Schumock
GT
,
Antoon
JW
.
The relationship between Oseltamivir and suicide in pediatric patients
.
Ann Fam Med
.
2018
;
16
(
2
):
145
148
15.
Zima
BT
,
Gay
JC
,
Rodean
J
, et al
.
Classification System for International Classification of Diseases, Ninth Revision, Clinical Modification and Tenth Revision Pediatric Mental Health Disorders
.
JAMA Pediatr
.
2020
;
174
(
6
):
620
622
16.
Feudtner
C
,
Feinstein
JA
,
Zhong
W
,
Hall
M
,
Dai
D
.
Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation
.
BMC Pediatr
.
2014
;
14
:
199
17.
Blumentals
WA
,
Song
X
.
The safety of Oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons
.
MedGenMed
.
2007
;
9
(
4
):
23
18.
Wakabayashi
T
,
Nakatsuji
T
,
Kambara
H
, et al
.
Drug-induced neuropsychiatric adverse events using post-marketing surveillance
.
Curr Clin Pharmacol
.
2021
19.
Rogers
JP
,
Chesney
E
,
Oliver
D
, et al
.
Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic
.
Lancet Psychiatry
.
2020
;
7
(
7
):
611
627
20.
Green
MS
.
Use of predictive value to adjust relative risk estimates biased by misclassification of outcome status
.
Am J Epidemiol
.
1983
;
117
(
1
):
98
105
21.
Antoon
JW
,
Grijalva
CG
,
Thurm
C
, et al
.
Factors associated with COVID-19 disease severity in US children and adolescents
.
J Hosp Med
.
2021
;
16
(
10
):
603
610
22.
Sato
K
,
Mano
T
,
Iwata
A
,
Toda
T
.
Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
.
Biosci Trends
.
2020
;
14
(
2
):
139
143
23.
Clarridge
K
,
Chin
S
,
Eworuke
E
,
Seymour
S
.
A boxed warning for Montelukast: the FDA perspective
.
J Allergy Clin Immunol Pract
.
2021
;
9
(
7
):
2638
2641

Supplementary data